Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.

Front Immunol · 2026 · PMC13272384 · PMID 42317338

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the KEYNOTE-789 study, in the PD-L1-positive subgroup, the Pembrolizumab plus chemotherapy group showed a trend toward improved OS ( 23 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.